Mitesh J. Borad, MD

Division of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ, USA

Mitesh J. Borad received his B.S. in Biomedical Engineering from Boston University in 1996, and M.D. from Rutgers New Jersey Medical School in 2000. After completing his internal medicine training at Cedars-Sinai Medical Center in Los Angeles and medical oncology training at Tulane University School of Medicine in New Orleans, he was a Genomics Medicine and Drug Development Scholar at the Translational Genomics Research Institute (TGen) in Phoenix under the tutelage of Dr. Daniel Von Hoff. His research efforts are focused on development of novel therapeutics in liver, biliary and pancreatic cancers by leveraging Next-gen whole genome sequencing approaches, as well as application of emerging areas, such as the use of recombinant viruses with oncolytic/immunotherapeutic properties. His group was the first to introduce an oncolytic Rhabdovirus into human clinical studies, and further development of this exciting area will be a focus of his efforts. His team was also the first to demonstrate anti-tumor activity in patients with FGFR2-fusion cholangiocarcinomas using small molecule FGFR2 inhibitors. His work is supported by grants from the National Institutes of Health (NIH), National Cancer Institute (NCI) and U.S. Food and Drug Administration (FDA). He currently directs the GI Cancer Gene Therapy and Oncolytic Virus Lab at Mayo Clinic Cancer Center in Phoenix. He also serves on the NIH Drug Discovery and Pharmacology (DMP) Study Section as a Standing Member, NIH Hepatobiliary Cancer Task Force, Vice Chair of the International Cholangiocarcinoma Research Network (ICRN) and Editorial Board Member of SGO, the official journal of International Association of Surgeons, Gastroenterologists and Oncologists (IASGO).